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Abstract
Introduction Gender as a predictor of outcomes of rheumatoid
arthritis (RA) has evoked considerable interest over the
decades. Historically, there is no consensus whether RA is
worse in females or males. Recent reports suggest that females
are less likely than males to achieve remission. Therefore, we
aimed to study possible associations of gender and disease
activity, disease characteristics, and treatments of RA in a large
multinational cross-sectional cohort of patients with RA called
Quantitative Standard Monitoring of Patients with RA (QUEST-
RA).
Methods The cohort includes clinical and questionnaire data
from patients who were seen in usual care, including 6,004
patients at 70 sites in 25 countries as of April 2008. Gender
differences were analyzed for American College of
Rheumatology Core Data Set measures of disease activity,
DAS28 (disease activity score using 28 joint counts), fatigue,
the presence of rheumatoid factor, nodules and erosions, and
the current use of prednisone, methotrexate, and biologic
agents.
Results Women had poorer scores than men in all Core Data
Set measures. The mean values for females and males were
swollen joint count-28 (SJC28) of 4.5 versus 3.8, tender joint
count-28 of 6.9 versus 5.4, erythrocyte sedimentation rate of 30
versus 26, Health Assessment Questionnaire of 1.1 versus 0.8,
visual analog scales for physician global estimate of 3.0 versus
2.5, pain of 4.3 versus 3.6, patient global status of 4.2 versus
3.7, DAS28 of 4.3 versus 3.8, and fatigue of 4.6 versus 3.7 (P
< 0.001). However, effect sizes were small-medium and
smallest (0.13) for SJC28. Among patients who had no or
minimal disease activity (0 to 1) on SJC28, women had
statistically significantly higher mean values compared with men
in all other disease activity measures (P  < 0.001) and met
DAS28 remission less often than men. Rheumatoid factor was
equally prevalent among genders. Men had nodules more often
than women. Women had erosions more often than men, but the
statistical significance was marginal. Similar proportions of
females and males were taking different therapies.
Conclusions In this large multinational cohort, RA disease
activity measures appear to be worse in women than in men.
However, most of the gender differences in RA disease activity
may originate from the measures of disease activity rather than
from RA disease activity itself.
Introduction
The possible influence of gender and gender-related variables
on the phenotype, severity, and prognosis of rheumatoid arthri-
tis (RA) appears to be of considerable interest [1]. Severe clin-
ical disease activity, structural damage, and deformities have
been reported equally in both genders in RA [2-6]. Generally,
however, women report more severe symptoms [7] and
greater disability [8] and often have higher work disability rates
[9] compared with men. As in the general population, men with
RA have considerably higher mortality rates than women [10].
However, the clinical status of RA patients at this time is
improved compared with previous decades, according to dis-
ease activity [11,12] and function and structural outcomes
[12-17], generally with no gender differences.
Analyses of gender differences of RA include a study that indi-
cates less favorable status in men [18] and many studies with
less favorable status in women [19-23]. Some recent studies
suggest that men have better responses to treatments with
biologic agents than women [19-21], and other studies indi-
cate that male gender is a major predictor of remission in early
RA [22,23]. However, men have been shown to experience a
greater number of adverse effects, particularly serious infec-
tions during biologic treatments [24,25]. Similar treatment
goals have been advocated for both genders [26].
Gender differences in disease activity and other measures
may reflect the properties of measures [27] as females have
higher erythrocyte sedimentation rates (ESRs) than males [28]
and poorer scores on most questionnaires [7]. Further infor-
mation concerning the possible influence of gender on the
clinical status and disease activity measures of RA appears to
be of value. Therefore, we explored possible associations of
gender and disease activity measures, treatments, and clinical
characteristics of RA in a large multinational cross-sectional
cohort of patients with RA [29], as presented in this report.
Materials and methods
The Quantitative Standard Monitoring of Patients with RA
(QUEST-RA) program was established in 2005 to promote
quantitative assessment in usual clinical care at multiple sites
and to develop a database of RA patients seen outside of clin-
ical trials in regular care in many countries. The initial design
was to assess 100 patients with RA at each of three or more
sites in 10 different countries, with data collection beginning
in January 2005. The program has since been expanded to
include 6,004 patients from 70 sites in 25 countries as of April
2008. This report [29] includes data from Argentina, Brazil,
Canada, Denmark, Estonia, Finland, France, Germany,
Greece, Hungary, Ireland, Italy, Kosovo, Latvia, Lithuania, The
Netherlands, Poland, Russia, Serbia, Spain, Sweden, Turkey,
United Arab Emirates, the UK, and the US. The study was car-Available online http://arthritis-research.com/content/11/1/R7
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ried out in compliance with the Declaration of Helsinki. Ethics
committees or internal review boards of participating institutes
approved the study, and informed consent was obtained from
the patients.
Clinical evaluation
All patients were assessed according to a standard protocol
to evaluate RA (SPERA) [30]. Physicians completed three
one-page forms: (a) review of clinical features, including clas-
sification criteria, extra-articular features, comorbidities, and
relevant surgeries; (b) all previous and present disease-modi-
fying antirheumatic drugs (DMARDs), their adverse events,
and reasons for discontinuation; and (c) a 42-joint count [31]
for swollen and tender joints as well as joints with limited
motion or deformity. The review included physician global
assessment of disease activity, physician report concerning
whether or not the patient had radiographic erosions, and lab-
oratory tests of ESR, C-reactive protein (CRP), and rheuma-
toid factor (RF) values.
Patient self-report
Patients completed a four-page expanded self-report ques-
tionnaire that included the standard Health Assessment Ques-
tionnaire (HAQ) [32] as well as items from the
multidimensional HAQ (MDHAQ) [33], HAQ II [34], and the
Recent-Onset Arthritis Disability questionnaire to assess func-
tional capacity in activities of daily living [35]. The question-
naire also includes visual analog scales (VASs) for pain,
patient global status, and fatigue; RA disease activity index
(RADAI) self-report joint count [36]; duration of morning stiff-
ness; lifestyle choices such as smoking and physical exercise;
height and weight to calculate body mass index; and demo-
graphic data, including years of education and work status
[29].
Gender and disease activity measures
DAS28 was calculated for current disease activity [37,38]
according to 28 swollen (SJC28) and tender (TJC28) joint
counts from the formula DAS28 = 0.56*sqrt(TJC28) +
0.28*sqrt(SJC28) + 0.70*Ln(ESR) + 0.014*patient global 0
to 100. DAS28 remission rates (DAS28 of less than 2.6) were
calculated for females and males. The HAQ score was calcu-
lated without including 'aids and devices' and 'help from other
people' given that the availability of aids/devices may differ
across countries in a multicultural study such as QUEST-RA.
It has been suggested that the HAQ may be calculated with-
out aids/devices/help since inclusion might result in bias.
The proportion of patients who met DAS28 criteria for remis-
sion (<2.6) was analyzed in females and males with 0, 1, 2, 3,
4, and 5 swollen joints on a 28-joint count. Levels of individual
disease activity measures were calculated for females and
males according to SJC28 in arbitrary categories of 0 to 1, 2
to 3, 4 to 6, and 7 or more swollen joints. Swollen joint count
was chosen as the standard, although a 'gold standard' meas-
ure for disease activity does not exist.
Gender and disease characteristics
Gender differences in disease characteristics, including the
prevalence of RF+, nodules, and erosive disease, were studied
separately in two groups of countries: 'low' prevalence and
'high' prevalence countries. For example, the prevalence of
RF+ ranges between 52% and 92% among countries, with a
median of 73.5%. Thus, all countries with a 'low' prevalence of
RF+ of between 52% and 73.5% were analyzed together for
gender differences of RF+, and countries with a 'high' preva-
lence of RF+ of between 73.5% and 92% were analyzed
together for gender differences of RF+. Two groups of coun-
tries ('low' versus 'high' prevalence) were formed similarly to
analyze nodules (cut point for prevalence = 20%) and erosive
disease (cut point for prevalence = 63%).
Gender and therapies for rheumatoid arthritis
The percentage of patients who were taking prednisone,
methotrexate, and biologic agents for RA differed considerably
between countries. To study whether females were treated dif-
ferently from males, countries were studied in two groups,
such as for disease characteristics, divided at the median
among the 25 countries. Thus, countries with 'low use of a
drug' and 'high use of a drug' were analyzed separately. Medi-
ans were 50% for prednisone, 62% for methotrexate, and
18% for biologic agents. The delay between the first RA symp-
toms and initiation of the first DMARDs was calculated and
compared between men and women.
Statistical methods
Results for continuous variables are presented as mean,
standard deviation, median, and percentages. Statistical sig-
nificance was tested with the Student t test and nonparametric
tests for continuous variables and the chi-square test for cate-
gorical variables. The association of gender and outcome var-
iables was calculated for each variable and each country.
Effect size was estimated according to two methods: in stand-
ardized units of difference (Cohen's D) and variance-
accounted statistics (eta-squared [η2]). Ninety-five percent
confidence intervals for Cohen's D were obtained by bias-cor-
rected bootstrapping (1,000 replications) and for η2 by non-
centrality-based interval estimation. η2 was calculated using
an analysis of covariance model that adjusts for age, disease
duration, and country. Cohen's D standards are small effect
0.2, medium effect 0.5, and large effect 0.8. For η2, standards
are small effect 0.01, medium effect 0.059, and large effect
0.138.
Results
Demographic and clinical characteristics
In April 2008, the QUEST-RA database included 6,004
patients from 70 sites in 25 countries. The demographic char-
acteristics are those of a typical RA cohort with 79% females,Arthritis Research & Therapy    Vol 11 No 1    Sokka et al.
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more than 90% Caucasians, and a mean age of 57 years
(Table 1), with considerable variation between countries. Sig-
nificant variation between countries was seen in disease activ-
ity, severity, and treatments (Table 1).
Gender differences in disease activity in the entire group
Women had higher scores (indicating poorer status) than men
in all Core Data Set measures. The mean values for females
and males were SJC28 of 4.5 versus 3.8, TJC28 of 6.9 versus
5.4, ESR of 30 versus 26, HAQ (0 to 3) of 1.1 versus 0.8, vis-
ual analog scales (0 to 10) for physician global estimate of 3.0
versus 2.5, pain of 4.3 versus 3.6, and patient global estimate
of 4.2 versus 3.7 (P < 0.001). DAS28 (0 to 10) was 4.3 in
females versus 3.8 in males, and fatigue was 4.6 versus 3.7 (P
< 0.001). Variables were also compared using nonparametric
tests, with identical levels of statistical significance. Cohen's D
effect size of gender was at a medium level (0.2 to 0.5) for
HAQ physical function (0.43) followed by DAS28 and fatigue
(0.33), pain (0.27), physician global estimate (0.23), tender
joint count (0.21), and patient global estimate (0.20) and was
at a low level (<0.20) for swollen joint count and ESR (0.13 for
both). According to η2 statistics, the effect of gender was
small-medium for all studied variables (Figure 1).
Among the disease activity measures that were studied,
SJC28 levels appeared to be most similar between genders.
Therefore, other disease activity measures were compared on
different SJC28 levels. Among patients who had 0 to 1 swol-
len joints, women had statistically significantly higher mean val-
ues compared with men for all other disease activity measures
(P < 0.001) (Table 2). Among patients who had 2 to 3 swollen
joints, women had significantly higher scores than men in all
other measures except TJC and ESR (Table 2). At higher lev-
els of SJC28, differences were most pronounced in pain,
fatigue, and HAQ.
More men (30.0%) than women (16.7%) were in DAS28
remission (P < 0.001). Among patients with 0 swollen joints,
57.6% of men and 42.0% of women were in DAS28 remis-
sion. Among patients with 1 and 2 swollen joints, 30.3% and
20.2% of men and 16.9% and 7.1% of women met DAS28
remission, respectively (P < 0.001) (Figure 2). Around 15% of
men and 5% of women met criteria for DAS28 remission even
when they had 3 to 4 swollen joints on a 28-joint count.
Gender differences in disease activity measures 
according to country
Standardized units of difference between genders were calcu-
lated for each variable according to country and are shown as
an example for two variables: HAQ (Table 3) and DAS28
(Table 4). Differences according to gender were greatest on
the HAQ (of all Core Data Set measures); females had poorer
scores compared with men in all but one country. The effect
sizes of gender were high (Cohen's D > 0.5) in 5 countries,
medium (0.2 to 0.5) in 16 out of 25 countries, and low (<0.2)
in 4 countries (Table 3). For DAS28, the differences between
scores according to gender were high in 2 countries, medium
in 9 countries, and low in 14 out of 25 countries (Table 4).
Gender and disease characteristics
RF was equally prevalent among females and males, including
'low' (females 67.2% versus males 69.5%; P = 0.29) and
'high' (79.6% versus 80.0%; P = 0.86) prevalence countries.
Men (24.1%) had rheumatoid nodules more often than women
(19.3%). Erosions were more prevalent among women than
men (64.3% versus 59.7%; P = 0.003), although the differ-
ence was not statistically significant in 'low' prevalence coun-
tries (53.6% versus 51.6%; P = 0.36) and was only marginally
significant in 'high' prevalence countries (76.7% versus
71.9%;  P  = 0.041). Men were smokers more often than
women: 27.2% versus 14.8% (P < 0.001).
Gender and therapies for rheumatoid arthritis
In 'low use' countries, similar percentages of women and men
were currently taking prednisone (30.0% versus 31.0%),
methotrexate (54.1% versus 54.7%), and biologic agents
(7.9% versus 8.1%). Similar proportions of women and men
were taking these drugs in 'high use' countries; the percent-
ages were 60.6% versus 61.5% for prednisone, 68.4% versus
72.0% for methotrexate, and 29.1% versus 30.8% for biologic
agents, respectively. Similar percentages of women and men
had ever taken these drugs over the course of RA (data not
shown). The delay between the first RA symptoms and initia-
tion of DMARDs was 10 months in the entire group, with con-
siderable variation between countries (Table 1); no statistically
significant gender differences within countries were seen
(data not shown).
Discussion
Obvious differences between genders exist in the prevalence,
age at onset, and autoantibody production of RA [39]. The
majority of patients with RA are middle-aged women, generally
greater than 70% in any RA cohort (including the present
study), although RA can occur at any age in either gender. Fur-
thermore, gender differences are seen in biologic (hormones)
[40] and behavioral (smoking) [41,42] factors that may influ-
ence susceptibility and phenotype of RA.
As noted before, the natural history of RA when limited treat-
ment options were available involved severe outcomes in most
patients without major gender differences. However, occa-
sional reports of gender differences in RA with unexpected
results or interpretations appear to have gained more attention
than reports of no gender differences. Ten years ago, a study
from the Mayo Clinic [18] compared 55 male patients with
110 female controls with similar disease duration of at least 10
years. Erosive disease was more prevalent and developed ear-
lier in men than in women. Nodules and lung disease were
more frequent in men and sicca syndrome was more frequent
in women [18]. The investigators suggested that the findingsA
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Table 1
Patient demographic and clinical characteristics in the QUEST-RA Study by country
Country Sites Patients Female, 
percentage
Age, 
years
Disease duration, 
years
DMARD delay, 
months
RF+, 
percentage
Smoking now, 
percentage
DAS28 SJC28 ESR Pain Patient global HAQ Taking now, percentage
Pred MTX Any biologic
Netherlands 3 317 66.3 59.2 9.2 6.0 68.8 22.9 3.1 1.0 15.0 2.5 2.7 0.8 16.1 74.1 19.6
Finland 3 304 72.4 58.5 13.5 7.0 74.8 15.5 3.3 1.0 13.0 2.8 2.8 0.6 51.3 61.5 12.5
USA 3 301 72.9 57.5 9.3 9.0 70.9 20.5 3.3 2.0 14.0 3.2 2.6 0.6 60.1 71.8 27.6
Greece 3 300 75.7 58.1 11.8 7.0 52.1 15.8 3.4 0.0 23.0 2.3 2.0 0.3 70.7 71.3 47.0
Denmark 3 301 76.7 57.8 12.0 11.0 73.3 31.6 3.4 1.0 14.0 2.6 2.8 0.6 14.6 71.1 21.3
Spain 3 302 73.5 59.8 10.6 14.0 72.5 17.8 3.5 1.0 17.0 3.1 3.6 0.9 46.7 56.3 23.2
France 4 389 77.9 55.3 12.8 8.0 75.3 19.1 3.7 1.0 16.0 3.9 3.6 0.9 60.9 57.1 44.2
Sweden 3 260 71.8 59.4 12.5 12.0 81.6 19.2 3.8 2.0 19.0 3.3 3.3 0.9 41.2 65.8 26.9
UK 3 145 77.9 59.6 15.0 16.0 81.4 19.4 4.0 1.0 19.0 4.1 3.6 0.9 28.3 70.3 14.5
Ireland 3 240 64.3 56.4 11.3 11.0 79.6 24.6 4.1 3.0 18.0 3.4 2.9 0.8 31.7 71.7 32.1
Canada 1 100 78.8 57.9 12.4 11.0 82.8 30.0 4.1 2.0 21.0 4.6 4.0 1.0 25.0 49.0 23.0
Turkey 3 309 85.6 52.2 11.6 12.0 67.6 14.1 4.2 0.0 30.0 4.2 4.6 0.9 57.3 69.3 5.8
Brazil 3 115 88.6 52.3 8.5 8.0 79.6 13.3 4.2 3.0 28.0 3.2 3.5 0.6 53.9 80.0 25.2
UAE 2 199 85.8 45.3 6.4 11.7 75.4 6.3 4.3 3.0 23.5 3.7 2.8 0.6 35.2 53.3 7.5
Germany 3 225 83.6 58.8 13.4 15.0 60.9 13.5 4.4 3.0 20.0 5.0 4.9 0.8 26.7 45.8 22.7
Italy 4 336 78.2 61.0 10.5 9.0 71.4 15.9 4.5 2.0 28.0 4.9 5.0 1.0 51.8 53.3 12.5
Estonia 3 168 85.5 55.8 11.8 12.0 68.1 14.0 4.7 4.0 24.0 4.3 4.8 1.1 43.5 53.6 0.6
Russia 3 73 84.5 54.2 6.2 10.0 74.6 15.4 5.0 5.0 24.0 3.6 4.5 1.1 38.4 46.6 16.4
Hungary 3 153 87.4 57.9 12.6 12.0 92.8 25.3 5.1 5.0 26.0 5.2 5.1 1.4 36.6 62.7 12.4
Latvia 1 79 79.7 53.2 13.2 32.1 84.6 19.2 5.2 4.0 26.0 5.1 5.7 1.4 63.3 70.9 21.5
Poland 7 642 86.7 53.2 11.5 4.0 70.3 11.9 5.3 6.0 31.0 5.0 4.8 1.4 58.9 65.0 6.1
Argentina 2 246 90.2 51.4 9.9 13.0 90.5 21.4 5.3 9.0 30.0 5.0 4.7 1.0 63.4 48.8 2.8
Lithuania 2 300 82.9 54.1 10.7 15.0 78.4 7.1 5.5 3.0 29.0 5.2 5.3 1.4 82.7 55.7 9.3
Serbia 1 100 88.0 59.2 10.1 11.1 71.4 18.4 5.9 6.0 28.0 5.1 5.3 1.6 54.0 54.0 0.0
Kosovo 1 100 84.0 55.0 7.8 3.0 80.6 10.4 6.0 6.0 45.0 5.1 5.0 1.6 90.0 71.0 1.0
Total 70 6,004 79.2 56.2 11.2 10.0 73.6 17.4 4.2 2.0 22.0 4.1 4.2 0.9 49.1 62.5 18.3
Mean values are presented for age, disease duration, and disease activity score using 28 joint counts (DAS28). Median values are presented for other continuous variables. DMARD, disease-modifying 
antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; Pred, prednisone; QUEST-RA, Quantitative Standard Monitoring of Rheumatoid 
Arthritis; RF, rheumatoid factor; SJC, swollen joint count; UAE, United Arab Emirates.Arthritis Research & Therapy    Vol 11 No 1    Sokka et al.
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might help 'assess the prognosis and tailor the treatment of
the individual patient' with a reaction from the rheumatology
community [1].
Our results are consistent with the results of recent studies
that indicate major gender differences in DAS28 remission
rates: overall, 30% of men and 17% of women in QUEST-RA
were in DAS28 remission. Differences were striking in patients
who had no swollen joints: much fewer women than men (42%
versus 58%) met DAS28 remission. At SJC28 levels of 0 to 1,
which indicate no or very little clinical disease activity, gender
differences were significant both clinically and statistically in
all other American College of Rheumatology (ACR) Core Data
Set measures and fatigue. On the other hand, gender differ-
ences in measures were less pronounced or nonexistent on
higher disease activity levels (that is, higher SJC28 counts)
(Table 2). Therefore, recent observations of higher DAS28
remission rates [22,23] and treatment responses in males [19-
21] may reflect considerable differences in the measures
between genders [27,43-45], including normal ESR levels,
which are higher in females than males (especially in older age
groups) [28]. Furthermore, women report more symptoms and
Figure 1
Differences according to gender among clinical variables in the  QUEST-RA Study, adjusted for age, disease duration, and country Differences according to gender among clinical variables in the 
QUEST-RA Study, adjusted for age, disease duration, and country. 
DAS28, disease activity score using 28 joint counts; ESR, erythrocyte 
sedimentation rate; HAQ, Health Assessment Questionnaire; MDglo-
bal, doctor global assessment; QUEST-RA, Quantitative Standard 
Monitoring of Rheumatoid Arthritis; SJC28, swollen joint count-28; 
TJC28, tender joint count-28.
Table 2
Differences in disease activity measures between females and males in the QUEST-RA Study according to the number of swollen 
joints
Number of swollen joints Mean (standard deviation)
DAS28 TJC28 ESR MD global Pain Patient global Fatigue HAQ
0–1
Female 3.2 (1.2) 3.2 (5.3) 24 (19) 1.6 (1.8) 3.3 (2.6) 3.3 (2.5) 3.9 (2.9) 0.83 (0.75)
Male 2.7 (1.2) 2.0 (3.9) 20 (21) 1.2 (1.5) 2.6 (2.5) 2.9 (2.6) 2.9 (2.7) 0.52 (0.62)
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2–3
Female 4.2 (1.1) 5.2 (5.4) 29 (22) 2.8 (1.9) 4.1 (2.6) 4.1 (2.4) 4.5 (2.8) 1.1 (0.71)
Male 3.8 (1.2) 4.7 (5.7) 25 (26) 2.4 (1.8) 3.6 (2.4) 3.6 (2.3) 3.7 (2.6) 0.74 (0.62)
P value <0.001 0.26 0.11 0.013 0.010 0.010 0.001 <0.001
4–6
Female 4.8 (1.1) 7.3 (6.0) 31 (23) 3.5 (2.0) 4.7 (2.5) 4.6 (2.4) 5.0 (2.7) 1.2 (0.71)
Male 4.6 (1.3) 6.8 (6.2) 32 (27) 3.4 (2.0) 4.1 (2.5) 4.4 (2.4) 4.2 (2.7) 0.91 (0.64)
P value 0.071 0.28 0.63 0.041 0.017 0.29 <0.001 <0.001
≥ 7
Female 6.0 (1.2) 13 (8.0) 38 (25) 5.1 (2.1) 5.6 (2.5) 5.2 (2.5) 5.6 (2.6) 1.4 (0.75)
Male 5.8 (1.3) 12 (7.8) 38 (28) 4.9 (2.1) 5.2 (2.3) 4.9 (2.4) 5.0 (2.6) 1.2 (0.68)
P value 0.016 0.064 0.99 0.21 0.024 0.082 <0.001 <0.001
P values are from Student t test for independent samples. DAS28, disease activity score using 28 joint counts; ESR, erythrocyte sedimentation 
rate; HAQ, Health Assessment Questionnaire; MD global, doctor global assessment; QUEST-RA, Quantitative Standard Monitoring of 
Rheumatoid Arthritis; TJC28, tender joint count-28.Available online http://arthritis-research.com/content/11/1/R7
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poorer scores on most questionnaires [7], including scores for
pain [46], depression, and other health-related items [47,48].
Self-report performance in activities of daily living is a strong
predictor of further functional loss, work disability, and mortal-
ity in RA, in other conditions, and in the general population
[49]. HAQ is an important outcome measure in clinical trials
and in the documentation of patient status in clinical care [33].
Throughout the history of the HAQ, women have been found
to report poorer scores than men [8,50-53]. This is reasonable
as women are not as physically strong as men [54,55], which
has a major effect in the functional status of patients with RA
and of healthy persons [56]. In fact, gender differences in mus-
culoskeletal performance remain even among the best-trained
individuals – female and male athletes compete separately!
Given that women are a 'weaker vessel' concerning muscu-
loskeletal size and strength and their baseline values are lower
than those of men, the same burden of a musculoskeletal dis-
ease may be more harmful to a woman than to a man.
Possible reasons for gender differences in RA have been
sought on the basis of sex hormones. Disease activity is amel-
iorated in 75% of women in pregnancy, and after delivery,
flares occur in up to 90% [57]. Oral contraceptives may pro-
tect against RA [58]. Hormone replacement therapy appears
to be beneficial concerning RA disease activity [59]. Estrogen
has a dichotomous impact on the immune system by downreg-
ulating inflammatory immune responses and upregulating
immunoglobulin production [60]. On the other hand, sex hor-
mone metabolism in RA synovial tissues may be unfavorable
for females; tumor necrosis factor inhibitors alter sex hormone
metabolism in the synovial tissue [61]. The beneficial effects
include restored levels of synovial androgens although
restored androgenic (immunosuppressive) activity may
explain, in part, the higher likelihood of men to develop serious
infections during biologic treatments [24,25].
Radiographs provide a permanent measure of the structural
damage of RA, radiographic scores are associated with cer-
tain disease activity measures [62]. Gossec and colleagues
[63] found no statistically significant differences in radio-
graphic outcomes between genders. In the BARFOT (Better
Anti-rheumatic Farmacotherapy) study [64] of patients with
early RA, erosive disease was present in 27% of men and
28% of women at the time of diagnosis. Similar percentages
of females and males were free of any radiographic changes
over the course of 2 years [64], and radiographic scores
remained similar between genders during the follow-up of 5
years [44]. In the extensive database of Wolfe and Sharp [65]
concerning number of patients and number of years, gender
was not among predictors of radiographic progression over
the course of two decades. These observations are consistent
with early studies from the 1980s [66] indicating that RA
presents similarly in both genders in case the extent of struc-
tural damage is chosen as the measure of disease severity.
There is a concern that women might be less likely to be
treated aggressively for RA compared with men. A report from
The Netherlands indicates a longer delay of referral of females
to an early arthritis clinic compared with men [67]. Several
reports from the cardiology literature indicate that men are
treated more intensively than women [68,69]. We did not find
significant differences in the proportion of females and males
who were taking prednisone, methotrexate, and biologic
agents in the QUEST-RA Study. Furthermore, the delay to ini-
tiation of therapies was similar for females and males within
countries.
Although QUEST-RA represents a unique program, several
limitations are recognized. All data were collected as part of
clinical care in different clinical environments and traditions to
examine and treat patients, which may vary greatly in the par-
ticipating countries. First, a central laboratory was not used for
blood samples, which instead were analyzed locally. There-
fore, for example, normal CRP was reported as '<10' in many
clinics and DAS28-CRP cannot be calculated for all patients;
CRP values of 0 to 9.9 provide DAS28 results different from
CRP = 10, especially on low DAS28 levels approaching crite-
ria for remission. Second, although radiographs were taken of
most patients, they were analyzed by treating rheumatologists
for erosive or nonerosive disease only, and quantitative scor-
ing was not performed. Third, a cross-sectional database may
not be ideal to study gender differences, and longitudinal
observations might provide a more accurate picture of gender
differences in RA, with follow-up of all long-term outcomes,
including mortality. Men tend to die earlier than women and
Figure 2
The proportion of males and females with 0 to 5 swollen joints in the  QUEST-RA Study who meet DAS28 criteria for remission The proportion of males and females with 0 to 5 swollen joints in 
the QUEST-RA Study who meet DAS28 criteria for remission. CI, 
confidence interval; DAS28, disease activity score using 28 joint 
counts; QUEST-RA, Quantitative Standard Monitoring of Rheumatoid 
Arthritis; SJC, swollen joint count.Arthritis Research & Therapy    Vol 11 No 1    Sokka et al.
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may therefore be 'left-censored' in cross-sectional databases,
rendering outcomes for men apparently better. Finally, the
QUEST-RA data may not be generalizable in all included (or
nonincluded) countries.
Conclusion
QUEST-RA data indicate that currently used disease activity
measures are higher in women than in men. Gender differ-
ences for DAS28, fatigue, and ACR Core Data Set measures
are most pronounced in patients with low swollen joint counts,
suggesting that (especially at low levels of disease activity)
one has to be cautious about interpretations of gender differ-
ences since disease activity measures themselves may be
contaminated by gender.
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